Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases.

British journal of cancer - 10 Jun 2014

Nagy E, Gajjar K B, Patel I I, Taylor S, Martin-Hirsch P L, Stringfellow H F, Martin F L, Phillips D H

Abstract excerpt

BACKGROUND: Tamoxifen has anti-oestrogenic and anti-tumour activity in the breast, but is oestrogenic and carcinogenic in the endometrium. It can induce experimental tumours by both hormonal and DNA-damaging mechanisms, but its carcinogenic mode of action in human endometrium remains unclear. METHODS: We investigated whether an epigenetic mechanism, involving promoter hypermethylation of the gene for the DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Modification Methylases
Share to DNA Repair Enzymes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Endometrium

Share to Estrogen Antagonists

Share to PTEN Phosphohydrolase

Share to Selective Estrogen Receptor Modulators

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 24853176
DOI: 10.1038/bjc.2014.263
PMCID: PMC4056065

Genes

PTEN
MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases.PMID 24853176Read ↗

Molecular genetics and endometrial cancer.Semantic proximity Read ↗

Molecular genetic characterization of tamoxifen-associated endometrial cancer.Semantic proximity Read ↗

Effects of tamoxifen on the endometrium and its mechanism of carcinogenicity.Semantic proximity Read ↗

Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma.Semantic proximity Read ↗

TP53 mutations in endometrial cancers: relation to PTEN gene defects.Semantic proximity Read ↗

Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomasSemantic proximity Read ↗

CHEK2, MGMT, SULT1E1 and SULT1A1 polymorphisms and endometrial cancer risk.Semantic proximity Read ↗

Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis.Semantic proximity Read ↗

Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development: a population-based study from northern Norway with long-term follow-up.Semantic proximity Read ↗

The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer.Semantic proximity Read ↗

Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial PrecancersSemantic proximity Read ↗

Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.